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a  b  s  t  r  a  c  t
Aim:  This  study  reports  a single-institutional  experience  treating  liver  metastases  with  stereotactic  body
radiation  therapy  (SBRT).
Materials  and methods:  107  patients  with  169  lesions  were  assessed  to determine  factors  predictive  for
local  control,  radiographic  response,  and  overall  survival  (OS).  Machine  learning  techniques,  univariate
analysis,  and the Kaplan-Meier  method  were  utilized.
Results:  Patients  were  treated  with  a relatively  low  median  dose  of  30  Gy  in  3 fractions.  Fractions  were
generally  delivered  once  weekly.  Median  biologically  effective  dose  (BED)  was  60  Gy, and  the  median
gross  tumor  volume  (GTV)  was  12.16  cc. Median  follow-up  was  7.36 months.  1-year  local  control  was
75% via  the Kaplan-Meier  method.  On  follow-up  imaging,  43%,  40%,  and  17%  of  lesions  were  decreased,
stable,  and  increased  in  size,  respectively.  1-year  OS  was  46% and  varied  by  primary  tumor,  with  median
OS of  34.3,  25.1,  12.5,  and  4.6 months  for ovarian,  breast,  colorectal,  and  lung  primary  tumors,  respectively.
Breast  and  ovarian  primary  patients  had  better OS  (p  <  0.0001),  and  lung  primary  patients  had  worse  OS
(p  = 0.032).  Higher  BED  values,  the  number  of  hepatic  lesions,  and larger  GTV  were  not  predictive  of  local
control,  radiographic  response,  or OS. 21%  of  patients  suffered  from  treatment  toxicity,  but  no  grade  ≥3
toxicity  was reported.
Conclusion: Relatively  low-dose  SBRT  for liver  metastases  demonstrated  efficacy  and  minimal  toxicity,
even  for patients  with  large  tumors  or multiple  lesions.  This  approach  may  be  useful  for  patients  in  whom
higher-dose  therapy  is  contraindicated  or associated  with  high  risk  for toxicity.  OS  depends  largely  on
the  primary  tumor.









Stereotactic body radiation therapy (SBRT), or stereotactic abla-
tive radiotherapy (SABR), is a radiation therapy technique that
delivers high doses of radiation in generally up to five treatments.
Expanding use of this technique has allowed for the treatment
of metastatic disease, resulting in local control and even survival
benefit in carefully selected patients.1–3 Metastases to the liver
are common, especially in colon cancer patients.4 Surgery remains
the standard of care for resectable tumors, but many patients are
deemed to be poor surgical candidates.5–8 Though chemotherapy
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ndertake surgical resection, only 10–20% of metastases can be
afely resected.9,10 Other patients may  consider alternative treat-
ent approaches, including radiofrequency ablation.11,12
Radiation-induced liver disease (RILD) remains the dose-
imiting toxicity for liver SBRT, but the RILD risk is proportional to
he mean dose delivered to the liver.13–15 For this reason, small hep-
tic lesions can be treated without significant risk for RILD if there
s at least 700 cc of liver receiving less than 15 Gy total dose.13,16–19
hough liver SBRT is generally well tolerated, other general gas-
rointestinal (GI) toxicity is possible.20
Prospective trials have published encouraging outcomes for
iver SBRT, with multiple trials demonstrating 1-year local con-
rol rates over 90%. Toxicity profiles have also been quite low,
ith multiple studies finding no cases of RILD after multiple
ears of follow-up.13,17,21–27 Follow-up of these patients has
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tus, extrahepatic disease control, increased radiation prescription
dose (>54–60 Gy), and increased biologically effective dose (BED)
(>100–150 Gy) were considered to be positive prognostic factors.
There have been a variety of dose-fractionation schemes in these
studies, which is partly explained by the differences in size of the
gross tumor volume (GTV) between patients. Other key factors of
heterogeneity in these studies include different primary sites of the
tumor, prior chemotherapeutic status, and the number of hepatic
lesions being treated.28–31 Liver function tests, including aspartate
aminotransferase (AST), alanine aminotransferase (ALT), and alka-
line phosphatase (AP), have also been investigated as factors to
predict the development of liver metastases or even the outcome of
SBRT, but results have been mixed.32–34 These differences perhaps
serve to underscore the wide range of patients who  suffer from
hepatic metastases and their correspondingly varied outcomes.
The purpose of this study is to report on a single institutional
experience of treating liver metastases in non-surgical candidates
with relatively low-dose SBRT. 107 patients with 169 total lesions
were analyzed with the specific purpose of determining factors pre-
dictive for local control, radiographic response, and overall survival
(OS), including dosimetric characteristics, primary disease site, and
liver function tests. Machine learning techniques were used for this
purpose, in addition to univariate analysis and the Kaplan-Meier
method. Toxicity data was also reported to demonstrate the safety
of this treatment modality.
2. Materials and methods
2.1. Patient eligibility
All patients treated with SBRT for liver metastases at our
institution from October 2007–January 2018 were considered
for inclusion. There were no significant changes to the treat-
ment approach over this time period. Inclusion criteria included
histology-proven solid tumor, and patients who were deemed not
to be optimal surgical candidates. Retrospective tumor character-
istics, including the use of chemotherapy within the previous six
months, the number of hepatic lesions, and the site of the primary
tumor were collected through a retrospective chart review. None
of these characteristics were used as exclusion criteria. Patient data
was anonymized and chart review was implemented to record
dosimetric data, including prescription dose, number of fractions,
GTV, planning target volume (PTV), and the %GTV and %PTV receiv-
ing the prescription dose of radiation. BED was calculated using
the linear quadratic model: BED = total dose*(1 + dose per fraction
/ /). The / for the tumor volume was chosen to be 10 Gy.
AST, ALT, and AP data were also recorded before and after treat-
ment when available. This analysis was exempt by the institutional
review board and conducted in accordance with their tenets.
2.2. Endpoints
Tracking follow-up data was completed through a standardized
protocol. The two primary endpoints of the study were over-
all survival and local control. In order to further describe the
disease process, extrahepatic progression, hepatic progression,
radiographic response, duration of follow-up, and time to local
failure were all recorded as secondary endpoints. Radiographic
response was scored as decrease, stability, or increase in the lesion
size. Local failure was defined as an increase in the size of the
metastatic lesion after SBRT according to post-treatment imaging,
such as CT, MRI, or PET-CT scans. The duration of local control was
calculated from the time of completion of SBRT. The time between
the pre-treatment lab values and the start of treatment and the time
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lso recorded. Pre-treatment labs were generally recorded about
wo months prior to the start of treatments, and post-treatment
abs were recorded approximately two months after the comple-
ion of treatment. Patients were generally followed with imaging
very two-three months. Follow-up appointments primarily con-
isted of medical oncologists and radiation oncologists.
.3. Treatment
All patients were positioned with a full-body vacuum-driven
mmobilization device custom fit at the time of 4-dimensional CT
imulation. After delineation of the GTV by the attending radia-
ion oncologist, an internal target volume (ITV) was  constructed
rom the 4DCT scan to account for motion of the tumor. Doses were
rescribed to the ITV. The treatment delivery techniques included
D forward planned non-coplanar static field apertures and non-
oplanar static arcs. Intensity-modulated radiation therapy and
olumetric modulated arc therapy inverse planned delivery tech-
iques were also considered. Treatments were delivered using
 MV  X-ray beams on a stereotactic radiosurgical linear accelera-
or with a microleaf collimator (2.5 mm–4  mm leaf width) and a six
egrees of freedom robotic couch for localization using cone-beam
T image guidance. Cone-beam CT was  used prior to the start of
reatment to assist with alignment of the patient and tumor. Cone-
eam CT was  also used during treatment as needed to correct for
ntra-fraction motion. Radiation therapy was  generally delivered in
nce-weekly fractions in an effort to reduce toxicity.
.4. Statistics
Statistical analyses were conducted for each treated lesion
or the endpoints of radiographic response and local control,
hereas data was analyzed by patient for determination of factors
redictive for overall survival. Techniques used during analy-
is included: decision tree analysis, K-nearest neighbors, linear
iscriminant analysis, Gaussian naïve Bayesian classifier, support-
ector machine, and linear and logistic regression. Kaplan-Meier
nalyses were used for time-dependent variables, including over-
ll survival. Only treatments with imaging follow-up were included
n the Kaplan-Meier analysis for local control. Such analyses were
onducted for each distinct primary site for the liver metastasis and
or other variables potentially predictive of local control (e.g. BED,
TV, and number of lesions). T-tests were conducted for binary
ariables, and an alpha value of 0.05 was used to signify statis-
ical significance. Acute and late toxicity findings were tabulated




107 patients with 169 lesions were included in the analysis. 87
f these patients had received chemotherapy within the previous
ix months. The primary disease site was quite varied, including at
east 19 patients with breast, lung, and colorectal primary tumors.
he number of lesions per patient ranged from one to four. 68 of
07 patients had only one lesion; 20 patients had two lesions; 14
atients had three lesions; and 5 patients had four lesions (Table 1).
.2. Dosimetric characteristicsPatients were treated with a median 30 Gy (18–45) in 3 frac-
ions (3–5). The most common treatment regimens were 30 Gy in 3
ractions (27%), 36 Gy in 3 fractions (27%), and 24 Gy in 3 fractions
18%). There was an average of 5.19 days between fractions. Median
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Table  1





Chemotherapy in the past 6 months 87 81%
Median age (years) 69







Mean lesions per patient 1.59 (1−4)
Patients with 1 lesion 68 64%
Patients with 2 lesions 20 19%
Patients with 3 lesions 14 13%
Patients with 4 lesions 5 5%
Table 2
Dosimetric characteristics are considered in detail.
Dosimetric characteristic
Median dose (Gy) 30 (18–45)
Median fractions 3 (3–5)
Median BED (Gy) 60 (28.8–112.5)
Mean days between fractions 5.19
Median GTV (cc) 12.16 (0.46–300)
Median PTV (cc) 46.5 (7.2–586.09)
Median %GTV receiving prescription dose 100 (96.1–100)
Median % PTV receiving prescription dose 96.74 (73.95–100)
Median PTV maximum cGy / fraction 1099 (598–1746)
Median PTV mean cGy / fraction 1053 (546–1643)
Median PTV minimum cGy / fraction 912 (285–1455)
Table 3
Outcomes regarding survival, tumor progression, local control, and radiographic
response are displayed.
Outcome Number Rate
Patients alive 16 15%
Patients deceased 91 85%
Median overall survival (months) 9.43 (0.1–64.43)
Hepatic progression 55 60%
No  hepatic progression 36 40%
Extrahepatic progression 78 80%
No  extrahepatic progression 20 20%
Patients with clinical follow-up 94 88%
Lesions with imaging follow-up 143 85%
Median follow-up time (months) 7.36
Local failure 25 15%
Radiographic response: size decreased 61 43%

























































Lesion size increased 25 17%
Median time to failure (months) 4.60
BED was 60 Gy (28.8–112.5), and since there were no restrictions
regarding tumor size, the GTV was quite varied, with a median
of 12.16 cc (0.46–300). Other dosimetric characteristics, including
PTV, PTV maximum, mean, and minimum, as well as the %GTV and
PTV receiving the prescription dose were recorded (Table 2).
3.3. Outcomes
Median OS was 9.4 months after a median follow-up time of 7.36
months (Fig. 1). There were 25 total cases of local failure (Table 3).
Using Kaplan-Meier analysis, 1-year OS was 46%, and 1-year local
control was 75%. 2-year local control was 73%, and local control at
the median follow-up time of 7.36 months was 81%. Local failure
occurred at a median 4.60 months after the completion of SBRT.
s
o
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 local failures occurred within 3 months and 23 total within 1
ear. Imaging follow-up was obtained in 88% of patients and after
5% of treatments. Treatments without imaging follow-up were not
ncluded in the Kaplan-Meier analysis. This resulted in the elimina-
ion of one patient from the subsequent analysis. 61 lesions (43%)
ecreased in size, 57 (40%) remained stable, and 25 (17%) increased
n size. Imaging follow-up showed that 55 patients (60%) had some
epatic progression, and 78 (80%) had extrahepatic progression.
.4. Predictive factors
Kaplan-Meier analysis was  conducted to determine predictive
actors for OS, local control, and radiographic response. Patient
edian survival varied by primary tumor, with median OS  of
4.3, 25.1, 12.5, and 4.6 months for ovarian, breast, colorectal, and
ung primary tumors, respectively (Fig. 2). Breast and ovarian pri-
ary patients had a statistically significant increase in OS relative
o the rest of the patient cohort, and lung primary patients had
orse overall survival. Colorectal primary patients had no differ-
nce in OS relative to the rest of the cohort. A similar analysis was
onducted for local control, again demonstrating improved local
ontrol for breast primary tumors and decreased local control for
ung primary tumors (Fig. 3). OS and local control between breast
nd lung primary tumors were also directly compared, showing
mproved results in breast primary tumors (Fig. 4, p < 0.0001 and
.032, respectively).
There was  no significant difference in local control rates with
igher BED values or the number of hepatic lesions, and there was
o significant difference between larger (GTV > 30 cc) or smaller
esions (p = 0.19). These variables were considered as continuous
ariables, and specific thresholds (e.g. BED > 50 or 60 Gy) were also
mployed in this analysis. Even so, no statistically significant pre-
ictors were found using these variables. Radiographic response
lso showed no differences between treatments with higher BED
alues, treatments for larger vs. smaller tumors, or the number of
epatic lesions. None of these factors were predictive of increase
r decrease on radiographic follow-up.
Machine learning techniques were utilized in order to attempt
o derive a predictive model for local failure. First, importance
esting was conducted, and pre-treatment lab values (AP, AST,
nd ALT) consistently showed the highest variable importance
actors for predicting local failure. Mean pre-treatment AP, AST,
nd ALT values and their corresponding ranges were found to
e 103.13 (43–253), 31.96 (14–113), and 29.93 (4–113), respec-
ively, and mean post-treatment values were 156.90 (32–748),
3.88 (14–144), and 37.82 (3–168), respectively. These lab val-
es increased after 74%, 62%, and 59% of treatments, and in 72%,
6%, and 51% of patients after treatment. Pre-treatment labs were
btained a median 2.60 months prior to treatment, and post-
reatment labs were reported at a median 1.68 months after
reatment. Six different machine learning techniques were used
o determine whether these values were predictive of local fail-
re, and the corresponding area under the curve and accuracy
f each model were as follows: classical machine learning for
ogistic regression (0.5, 0.83), decision tree analysis (0.57, 0.78),
-nearest neighbors (0.59, 0.79), linear discriminant analysis (0.5,
.84), Gaussian naïve Bayesian classifier (0.45, 0.64), and support-
ector machine (0.5, 0.84). None of these models offered sufficient
redictive power to conclusively denote these laboratory values as
redictive factors.
.5. ToxicityToxicity was  quite low after treatment, with 23 patients (21%)
uffering from either a grade 1 or 2 toxicity, and 36 total instances
f toxicity (21%) recorded for all analyzed treatments. Only 3
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Fig. 1. The Kaplan-Meier method was utilized to demonstrate overall survival (a) and local control (b).
fied bFig. 2. Overall survival was  stratipatients suffered from grade 2 toxicity, and no grade ≥3 toxicity
was reported. The most common toxicities were six patients (6%)
suffering from pain (1 grade 2) and four patients (4%) suffering from





990y all major primary tumor types.atiety and two  experienced diarrhea. Two  patients noted increased
atigue. There were no reported cases of pneumonitis or RILD, and
o other specific side effect was  experienced by more than one
atient.
R.O. Kowalchuk et al. Reports of Practical Oncology and Radiotherapy 25 (2020) 987–993
Fig. 3. Local control was demonstrated for all major primary tumor types.
mary Fig. 4. Overall survival (a) and local control (b) were improved with a breast pri4. Discussion
This study demonstrated 1-year local control of 75% with min-




991tumor, relative to a lung primary tumor (p < 0.0001 and p = 0.032, respectively).
etastases. These results were not dependent on GTV, BED, the
umber of treated lesions, or liver function tests, indicating that











































R.O. Kowalchuk et al. 
This analysis considered a relatively ill patient cohort, with 81%
of patients having received chemotherapy in the past 6 months
and a median age of 69 years. Further, 39 patients were treated
for at least two distinct lesions, and 73% of patients went on to
experience extrahepatic progression of the primary malignancy.
In this setting, it is unsurprising that the patients demonstrated a
relatively low median overall survival of 9.4 months. Other studies
have also found that overall survival is dependent on primary tumor
site.10,16 This patient cohort had a higher number of patients with
a primary lung tumor (20.6%), who experienced a median overall
survival of merely 4.6 months while patients with colorectal and
breast primary tumors experienced overall survival which more
closely approximates values previously reported in the literature
(12.5 and 25.1 months, respectively).
Local control rates from previous studies have ranged from
71%–92%, and the local control rate here was 75% at one year via the
Kaplan-Meier method.10,13,17,21–23 Two variables have often arisen
as predictive of local failure: dose and tumor volume (as measure
by GTV or lesion size). Further, the number of treated lesions has
often been discussed, with guidelines often recommending treat-
ing with SBRT only up to 3 lesions.31 In this study, none of these
factors were found to be predictive of local failure or overall sur-
vival. In fact, five patients were included with four lesions, and no
restrictions were made regarding GTV or lesion size. For this reason,
though the median GTV was only 12.16 cc, patients up to a GTV of
300 cc were included. Other studies have noted improved local con-
trol with small lesions of maximal diameter of 3 cm or less than 40
cc.,13,10 Even with a higher number of large lesions treated in this
study, no lesion size or GTV threshold was found to be predictive of
treatment. This indicates that low-dose SBRT could be considered
in carefully selected patients with large or multiple lesions.
Many studies have pointed towards higher doses as predictive
of local control, including analyses ranging from single-fraction to
six fraction treatment.21,22,28 Most authors have pointed towards
48–60 Gy delivered in three fractions as an optimal regimen, but
others have questioned whether the dose-fractionation scheme
may  also depend on the primary tumor histology.10 Due to the
significant differences in outcomes between the different primary
tumors found in this analysis, we agree that this hypothesis merits
further study. Outcomes in this study closely mirror those pre-
viously reported in the literature, and therefore 30 Gy in three
fractions may  also be an effective dose-fractionation scheme in
selected patients for whom surgical resection and/or higher dose
therapy may  be contraindicated. One potential limitation of this
study is that there may  have been too few patients with high
BED treatments in order to detect improved local control at high
BED thresholds. For instance, this analysis would not have demon-
strated improved local control with BED > 100 Gy since only two
patients receiving treatment with >100 Gy. Even so, we demon-
strate encouraging results that may  serve as a foundation for further
study.
Very low toxicity was noted with treatment. No cases of RILD
were noted, and there were no cases of grade ≥3 toxicity. While pre-
vious studies have noted similarly encouraging results,25,31 other
have noted instances of grade ≥3 toxicity. Bae et al. reported grade
3 or 4 complications in 7% of patients; however, a higher dose of
45−60 Gy in 3 fractions was utilized.28 The relatively low median
BED of 60 Gy and the prolonged mean days between treatments
of 5.19 likely contributed to the minimal toxicity reported in this
study. In fact, only 4 grade 2 toxicities were reported among all
treatments. These findings indicate that in settings in which the
prescription dose may  be limited (e.g. previous radiation or concern
for toxicity), treatment may  still be considered.
No conclusive results have been noted in the literature regard-
ing whether or not liver function tests are predictive of treatment
efficacy or toxicity.32–34 Though a number of machine learning
992Reports of Practical Oncology and Radiotherapy 25 (2020) 987–993
lgorithms were applied to the outcomes data, it was difficult to
onstruct a robust model due to the few local failures reported
n the cohort. Importance testing did consistently point towards
re-treatment ALT, AST, and AP as predictive of local failure, but
his result is insufficient to conclusively state whether or not these
alues should impact treatment decisions. Further study is rec-
mmended. In particular, a patient cohort specifically focused on
onsidering patients who have had local failure of liver SBRT would
e best suited to answer this question.
This analysis is primarily limited by the short duration of follow-
p and high fraction of patients who were lost to follow-up. This is
hiefly the result of the patients presenting with advanced stages
f disease and following up with a range of providers at different
acilities, including palliative care and primary care physicians. This
lso served to limit the duration of imaging follow-up. Additionally,
atients were treated with a range of dose-fractionation schemes.
 more consistent approach would have improved the subsequent
nalysis. Finally, the delineation of local failure as an increase in size
n imaging is an imprecise measure. Because many of these patients
uffered from heavy disease burdens and poor health status, biopsy
as not commonly pursued. Even so, a more regimented approach
o distinguishing local failure would have proven beneficial.
. Conclusions
This study demonstrated safety and efficacy in a large set of 169
iver lesions treated with SBRT, showing impressive local control
ven for patients with large tumors or multiple lesions. This points
owards the utility of low-dose treatment for non-surgical patients
n whom higher-dose therapy may  be contraindicated or associated
ith high risk for toxicity. In carefully selected patients, however,
ose escalation may  be advisable. Overall survival depends largely
n the primary tumor.
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